SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 10/20/2017 10:19:40 AM - Followers: 725 - Board type: Free - Posts Today: 27

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/11/2017 06:04:37 AM
IPIX News: Statement of Changes in Beneficial Ownership (4) 09/06/2017 06:27:18 PM
PostSubject
#200759  Sticky Note IPIX is looking for partnerships after P2's. petemantx 10/19/17 10:14:05 PM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#198202  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A TheHound 09/26/17 02:43:47 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#200791   I do think Celgene's Phase 3 failure intensifies seek the light 10/20/17 10:36:30 AM
#200789   Clearly working for those who have an agenda. Williamsc 10/20/17 10:11:33 AM
#200788   Agree, and that is a source of frustration seek the light 10/20/17 10:10:14 AM
#200786   Traders generally need the stock to go up septmike09 10/20/17 10:01:20 AM
#200785   A trader not an investor. My opinion!!! seek the light 10/20/17 09:59:38 AM
#200784   Great post! Thanks. DaubersUP 10/20/17 09:54:01 AM
#200781   You have lot of nerve. You come over Williamsc 10/20/17 09:28:35 AM
#200780   Amatuer there will be NO phase 1 for runninggirl2016 10/20/17 09:27:28 AM
#200779   Absolutely. Eom scottsmith 10/20/17 09:21:26 AM
#200778   yet another losing week - close to $5MM MXAMDUD 10/20/17 09:07:11 AM
#200777   Thank you for providing this information and showing petemantx 10/20/17 08:59:41 AM
#200776   Sell it and let a big pharmaceutical carry Matagordaville 10/20/17 08:44:20 AM
#200775   The Aspire deal is simply another extension of frrol 10/20/17 08:27:23 AM
#200773   Yes. The volatility comes from the fact that frrol 10/20/17 07:50:58 AM
#200772  Restored Time for the MEGA BULLS to step up scottsmith 10/20/17 07:33:24 AM
#200771   Innovation Pharmaceuticals Inc. is in the perfect position BooDog 10/20/17 06:57:31 AM
#200769   You mean there's risk in biotech, especially pre-revenue Relentless4ever 10/20/17 06:33:58 AM
#200768   yest NEJM had 2 articles and an editorial To infinity and beyond! 10/20/17 06:33:35 AM
#200767   Mongersen, GED 0301, already had unanswered safety questions LilBigKahuna 10/20/17 06:33:17 AM
#200766   “Celgene's Crohn's disease drug just failed Phase 3 Amatuer17 10/20/17 04:31:50 AM
#200765   Prurisol, Secretariat is headed toward a BIG WIN!!! georgejjl 10/20/17 03:11:57 AM
#200764   Psoriasis severe to clear within just 84 days georgejjl 10/19/17 11:21:41 PM
#200763   If that comes true...then P is sitting cozy DaubersUP 10/19/17 11:10:51 PM
#200761   Prurisol may be effective as a treatment for georgejjl 10/19/17 10:52:55 PM
#200760   I estimate that Prurisol at 300 mg per georgejjl 10/19/17 10:39:11 PM
#200759   IPIX is looking for partnerships after P2's. petemantx 10/19/17 10:14:05 PM
#200758   Calling 3 Phase 2 trials, across 3 separate LilBigKahuna 10/19/17 09:54:04 PM
#200757   Let's throw that market cap loss right into DaubersUP 10/19/17 09:53:35 PM
#200756   It's fascinating how volatile biotech is. Celegene DaubersUP 10/19/17 09:52:31 PM
#200754   LIKE..... DaubersUP 10/19/17 09:39:48 PM
#200753   Thanks for sharing Pete. Looking forward Matagordaville 10/19/17 09:22:42 PM
#200752   From when last candidate was enrolled in Prurisol petemantx 10/19/17 09:20:32 PM
#200751   The dark horse is still running. Prurisol Matagordaville 10/19/17 09:12:07 PM
#200750   Thanks you maybe right. News soon causing fud Williamsc 10/19/17 09:09:59 PM
#200749   My stink bids are in. Bring it on, Bun farrell90 10/19/17 09:07:46 PM
#200748   Interesting post Tom. “ The good rally Matagordaville 10/19/17 09:04:55 PM
#200746   So what are you hanging around for. Oh Williamsc 10/19/17 08:57:00 PM
#200745   Events in bio never arrive as quickly or Williamsc 10/19/17 08:40:57 PM
#200744   Not really, I don't gloat before the game sox040713 10/19/17 08:31:57 PM
#200742   exactly ! Well stated. TheBunny 10/19/17 08:15:24 PM
#200741   Aspire is selling into the OS, there is TheBunny 10/19/17 08:12:04 PM
#200740   AlanC, complete nonsense. 18% of today's volume was taas 10/19/17 07:41:10 PM
#200738   Every penny SP goes down directly impacts the scottsmith 10/19/17 07:09:19 PM
#200737   Who cares? .63 now and piercing $4.63 in alwaysdreaming 10/19/17 07:03:06 PM
#200736   If, if, if , if it does, it 58nout 10/19/17 06:56:04 PM
#200735   Thanks for confirming what most of us already know! sox040713 10/19/17 06:55:57 PM
#200734   Well that's a big hickey. Some day 58nout 10/19/17 06:52:09 PM
#200733   So? The current SP won't change trial progress sox040713 10/19/17 06:42:05 PM
#200732   So to answer you and Scott, I put BooDog 10/19/17 06:41:15 PM
#200731   I'm so glad I found this stock six sox040713 10/19/17 06:37:02 PM
PostSubject